We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Humoral immunological kinetics of severe acute respiratory syndrome coronavirus 2 infection and diagnostic performance of serological assays for coronavirus disease 2019: an analysis of global reports.
- Authors
Emeribe, Anthony Uchenna; Abdullahi, Idris Nasir; Shuwa, Halima Ali; Uzairue, Leonard; Musa, Sanusi; Anka, Abubakar Umar; Adekola, Hafeez Aderinsayo; Bello, Zakariyya Muhammad; Rogo, Lawal Dahiru; Aliyu, Dorcas; Haruna, Shamsuddeen; Usman, Yahaya; Muhammad, Habiba Yahaya; Gwarzo, Abubakar Muhammad; Nwofe, Justin Onyebuchi; Chiwar, Hassan Musa; Okwume, Chukwudi Crescent; Animasaun, Olawale Sunday; Fasogbon, Samuel Ayobami; Olayemi, Lawal
- Abstract
As the coronavirus disease 2019 (COVID-19) pandemic continues to rise and second waves are reported in some countries, serological test kits and strips are being considered to scale up an adequate laboratory response. This study provides an update on the kinetics of humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and performance characteristics of serological protocols (lateral flow assay [LFA], chemiluminescence immunoassay [CLIA] and ELISA) used for evaluations of recent and past SARS-CoV-2 infection. A thorough and comprehensive review of suitable and eligible full-text articles was performed on PubMed, Scopus, Web of Science, Wordometer and medRxiv from 10 January to 16 July 2020. These articles were searched using the Medical Subject Headings terms 'COVID-19', 'Serological assay', 'Laboratory Diagnosis', 'Performance characteristics', 'POCT', 'LFA', 'CLIA', 'ELISA' and 'SARS-CoV-2'. Data from original research articles on SARS-CoV-2 antibody detection ≥second day postinfection were included in this study. In total, there were 7938 published articles on humoral immune response and laboratory diagnosis of COVID-19. Of these, 74 were included in this study. The detection, peak and decline period of blood anti-SARS-CoV-2 IgM, IgG and total antibodies for point-of-care testing (POCT), ELISA and CLIA vary widely. The most promising of these assays for POCT detected anti-SARS-CoV-2 at day 3 postinfection and peaked on the 15th day; ELISA products detected anti-SARS-CoV-2 IgM and IgG at days 2 and 6 then peaked on the eighth day; and the most promising CLIA product detected anti-SARS-CoV-2 at day 1 and peaked on the 30th day. The most promising LFA, ELISA and CLIA that had the best performance characteristics were those targeting total SARS-CoV-2 antibodies followed by those targeting anti-SARS-CoV-2 IgG then IgM. Essentially, the CLIA-based SARS-CoV-2 tests had the best performance characteristics, followed by ELISA then POCT. Given the varied performance characteristics of all the serological assays, there is a need to continuously improve their detection thresholds, as well as to monitor and re-evaluate their performances to assure their significance and applicability for COVID-19 clinical and epidemiological purposes.
- Subjects
CORONAVIRUS diseases; COVID-19; GLOBAL analysis (Mathematics); MEDICAL subject headings; HUMORAL immunity; CHEMILUMINESCENCE immunoassay
- Publication
International Health (1876-3413), 2022, Vol 14, Issue 1, p18
- ISSN
1876-3413
- Publication type
Article
- DOI
10.1093/inthealth/ihab005